Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
List view / Grid view
graft-versus-host disease (GvHD)
MaaT013 was safe and generated complete or very good partial responses in a third of patients with steroid-refractory, gastrointestinal-predominant acute graft-versus-host disease.
Numerous developments are ongoing to make advanced therapy medicinal products (ATMPs) more accessible, effective and less expensive. Here, legal experts Robert Stephen and Jane Hollywood from CMS discuss the increasing prevalence of these highly regulated therapies and the challenges faced by innovators in this space.
A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant...